Ezetimibe – facts and myths Review article
Article Sidebar
Main Article Content
Abstract
Ezetimibe is selective inhibitor of intestinal cholesterol absorption by interacting with the transporter Niemann-Pick C1-like 1 protein (NPC1L1) responsible for intracellular cholesterol transport. In addition to its effect on exogenous cholesterol, ezetimibe increases the density of LDL receptors on the surface of hepatocytes, and thereby increases the uptake of endogenous cholesterol associated with LDL molecules. Ezetimibe significantly reduces total cholesterol, LDL cholesterol and triglycerides, as well as increase HDL cholesterol, therefore it is recommended as monotherapy as well as in combination therapy with statins for the treatment of hypercholesterolemia.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Sharp Collaborative Group; Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 2010; 160(5): 785-794.e10.
3. Cannon C.P., Blazing M.A., Giugliano R.P. et al.; IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015; 372(25): 2387-2397.
4. Rossebø A.B., Pedersen T.R., Allen C. et al.: Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am. J. Cardiol. 2007; 99(7): 970-973.
5. Pandor A., Ara R.M., Tumur I. et al.: Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J. Intern. Med. 2009; 265(5): 568-580.
6. Wu H., Shang H., Wu J.: Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2018; 60(2): 229-239.
7. Stolk M.F., Becx M.C., Kuypers K.C., Seldenrijk C.A.: Severe hepatic side effects of ezetimibe. Clin. Gastroenterol. Hepatol. 2006; 4: 908-911.
8. Tsujita K., Sugiyama S., Sumida H. et al.: Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. J. Cardiol. 2015; 66(4): 353-358.
9. Crea F., Niccoli G.: Ezetimibe and Plaque Regression. Cholesterol Lowering or Pleiotropic Effects? J. Am. Coll. Cardiol. 2015; 66(5): 508-510.